ISIS PHARMACEUTICAL (ISI BE) stock market data APIs
€61.8862
0(0%)
as of October 24, 2025
Try our APIs with
free plan!
ISIS PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ISI.BE.
Prev. Close
61.8862
Open
61.8862
High
61.8862
Low
61.8862
52 wk Range
22.5-62.54
Market Cap
3 685 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ISIS PHARMACEUTICAL data using free add-ons & libraries
Get ISIS PHARMACEUTICAL Fundamental Data
ISIS PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ISIS PHARMACEUTICAL News
New
Why Analysts Say Ionis Pharmaceuticals Story Is Shifting After Key Clinical and Regulatory Wins
Ionis Pharmaceuticals has seen its consensus analyst price target rise from approximately $73 to $77 following a series of recent updates. This modest upward revision comes after positive clinical tri...
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
CARLSBAD, Calif., October 23, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual To...
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Wall Street expects a year-over-year decline in earnings on lower revenues when Ionis Pharmaceuticals (IONS) reports results for the quarter ended September 2025. While this widely-known consensus out...
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
CARLSBAD, Calif., October 21, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis’ chief executive officer, was awarded the 2025 Lifet...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
